BACKGROUND: Tumour-infiltrating lymphocytes (TILs) have been shown to predict survival in numerous malignancies. The importance of TILs in primary pancreatic neuroendocrine tumours (NETs) and NET liver metastases (NETLMs) has not been defined. METHODS: We identified 87 patients with NETs and 39 with NETLMs who had undergone resection. Immunohistochemistry was performed to determine TIL counts. Recurrence-free survival (RFS) and overall survival (OS) were determined using the log-rank test. RESULTS: The median follow-up time was 62 months in NET patients and 48 months in NETLM patients. Vascular invasion and histologic grade were the only independent predictors of outcome for NETs and NETLMs, respectively. Analysis of intermediate-grade NETs indicated that a dense T cell (CD3+) infiltrate was associated with a median RFS of 128 months compared with 61 months for those with low levels of intratumoral T cells (P= 0.05, univariate analysis). Examination of NETLMs revealed that a low level of infiltrating regulatory T cells (Treg, FoxP3+) was a predictor of prolonged survival (P < 0.01, univariate analysis). CONCLUSIONS: A robust T cell infiltrate is associated with improved RFS following resection of intermediate-grade NETs, whereas the presence of more Treg correlated with shorter OS after treatment of NETLMs. Further study of the immune response to intermediate-grade NETs and NETLMs is warranted.
BACKGROUND: Tumour-infiltrating lymphocytes (TILs) have been shown to predict survival in numerous malignancies. The importance of TILs in primary pancreatic neuroendocrine tumours (NETs) and NET liver metastases (NETLMs) has not been defined. METHODS: We identified 87 patients with NETs and 39 with NETLMs who had undergone resection. Immunohistochemistry was performed to determine TIL counts. Recurrence-free survival (RFS) and overall survival (OS) were determined using the log-rank test. RESULTS: The median follow-up time was 62 months in NET patients and 48 months in NETLM patients. Vascular invasion and histologic grade were the only independent predictors of outcome for NETs and NETLMs, respectively. Analysis of intermediate-grade NETs indicated that a dense T cell (CD3+) infiltrate was associated with a median RFS of 128 months compared with 61 months for those with low levels of intratumoral T cells (P= 0.05, univariate analysis). Examination of NETLMs revealed that a low level of infiltrating regulatory T cells (Treg, FoxP3+) was a predictor of prolonged survival (P < 0.01, univariate analysis). CONCLUSIONS: A robust T cell infiltrate is associated with improved RFS following resection of intermediate-grade NETs, whereas the presence of more Treg correlated with shorter OS after treatment of NETLMs. Further study of the immune response to intermediate-grade NETs and NETLMs is warranted.
Authors: Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544
Authors: Bridget N Fahy; Michael D'Angelica; Ronald P DeMatteo; Leslie H Blumgart; Martin R Weiser; Irina Ostrovnaya; Mithat Gonen; William R Jarnagin Journal: Ann Surg Oncol Date: 2008-12-03 Impact factor: 5.344
Authors: Karl Y Bilimoria; Mark S Talamonti; James S Tomlinson; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem Journal: Ann Surg Date: 2008-03 Impact factor: 12.969
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: Nicola R Hardwick; Mary Carroll; Teodora Kaltcheva; Dajun Qian; Dean Lim; Lucille Leong; Peiguo Chu; Joseph Kim; Joseph Chao; Marwan Fakih; Yun Yen; Jonathan Espenschied; Joshua D I Ellenhorn; Don J Diamond; Vincent Chung Journal: Clin Cancer Res Date: 2014-07-01 Impact factor: 12.531
Authors: Annacarolina da Silva; Michaela Bowden; Sui Zhang; Yohei Masugi; Aaron R Thorner; Zachary T Herbert; Chensheng Willa Zhou; Lauren Brais; Jennifer A Chan; F Stephen Hodi; Scott Rodig; Shuji Ogino; Matthew H Kulke Journal: Pancreas Date: 2018-10 Impact factor: 3.327
Authors: Lei Cai; Theodoros Michelakos; Vikram Deshpande; Kshitij S Arora; Teppei Yamada; David T Ting; Marty S Taylor; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone Journal: Clin Cancer Res Date: 2019-01-22 Impact factor: 12.531
Authors: Steven C Katz; Rachel A Burga; Elise McCormack; Li Juan Wang; Wesley Mooring; Gary R Point; Pranay D Khare; Mitchell Thorn; Qiangzhong Ma; Brian F Stainken; Earle O Assanah; Robin Davies; N Joseph Espat; Richard P Junghans Journal: Clin Cancer Res Date: 2015-04-07 Impact factor: 12.531
Authors: Steven C Katz; Zubin M Bamboat; Ajay V Maker; Jinru Shia; Venu G Pillarisetty; Adam C Yopp; Cyrus V Hedvat; Mithat Gonen; William R Jarnagin; Yuman Fong; Michael I D'Angelica; Ronald P DeMatteo Journal: Ann Surg Oncol Date: 2012-09-26 Impact factor: 5.344